On July 3, 2024, GSK plc restructured its collaboration with CureVac, gaining full rights to develop mRNA vaccines for flu and COVID-19, while CureVac earns €400 million upfront and up to €1.05 billion in milestones. This new agreement reflects GSK's strategy to enhance its mRNA capabilities and prioritize vaccine development.